Navigation Links
Astellas Joins the National Pharmaceutical Council
Date:5/14/2013

WASHINGTON, May 14, 2013 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Astellas Scientific and Medical Affairs, Inc. (Astellas), a U.S. affiliate of Tokyo-based Astellas Pharma Inc., has joined the health policy research organization as its newest member.  

Located in Northbrook, Illinois, Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Jeffrey Bloss , M.D., vice president, scientific and medical affairs, will be the company's representative on the NPC board of directors.

"We welcome Dr. Bloss to our board of directors and are looking forward to Astellas' participation in NPC's activities," said NPC President Dan Leonard . "Their perspective will be an invaluable resource for NPC as we continue our mission to educate decision-makers about the tremendous value that the biopharmaceutical industry adds to the health and well-being of Americans."

NPC is actively engaged in conducting health care policy research on topics such as the challenges of individual patient treatment effects, the utilization of real-world evidence and comparative effectiveness research, and understanding the role and value of pharmaceuticals within the current and evolving payment and delivery models.

"We are at an important time of great change with a new health care law, the increasing individualization of drug treatments, and a change in the conversation about those treatments. I look forward to working with NPC as it meets these challenges," said Dr. Bloss. "The biopharmaceutical industry has such an important story to tell, so it is a critical time to be involved with NPC."

About the National Pharmaceutical Council:

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United Sates that supports medical innovation.  Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients.  For more information visit www.npcnow.org and follow NPC on Twitter @npcnow.


'/>"/>
SOURCE National Pharmaceutical Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Gift of Hope Organ & Tissue Donor Network Join Forces to Raise Awareness of Need for More Organ Donors in Illinois
2. Astellas and Gift of Hope Organ & Tissue Donor Network Join Forces to Raise Awareness of Need for More Organ Donors in Chicago
3. Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
4. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
5. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
6. Astellas to Drive PGA TOURs New Womens Initiative
7. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
10. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
11. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... ... Robert E. Burke, MD, PhD, had a successful career as a pediatrician ... could have led him down a much different path. , In his book, “Beyond ... Pediatrics,” Dr. Burke shares a personal account of the tribulations he encountered on his ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has long ... company involved in the underground testing of nuclear weapons. Years later, when her co-workers ... of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by agencies ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric company ... Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount Power ... customers and 2,250 RCEs at the time of acquisition. In the three years ...
(Date:2/27/2017)... San Francisco, CA (PRWEB) , ... February 27, ... ... transplant clinic serving San Francisco and environs, is proud to announce an upgrade ... research information on the upgraded Yelp page on topics as diverse as Platelet ...
Breaking Medicine News(10 mins):